我国糖尿病治疗领域取得重大突破，成果加速从实验室走向病床

Core Viewpoint - A research team from Shanghai has developed a groundbreaking technique for treating Type 1 Diabetes (T1D) by achieving islet function reconstruction and blood sugar self-regulation through minimally invasive transplantation of regenerated islets derived from both autologous and allogeneic stem cells, marking a significant advancement in diabetes treatment [3][4][8]. Research and Development - The research was conducted by a collaboration between the Second Affiliated Hospital of Naval Medical University and the Chinese Academy of Sciences, focusing on a new technology based on endodermal stem cells, which simplifies the differentiation process and reduces the time required for islet production from 40 days to 14 days [4][5]. - The developed "E-islet" product has received IND approval in both China and the United States, making it the only regenerative islet drug approved in both countries, with clinical trials progressing smoothly [5][8]. Clinical Applications - The clinical study documented the treatment of three T1D patients, including the world's first autologous and allogeneic islet transplantation for T1D, with one patient achieving clinical cure for over 26 months [7][8]. - The therapy has shown the potential to restore islet function and insulin independence in T1D patients, significantly improving blood sugar levels and reducing the risk of complications [8]. Industry Context - Shanghai is positioning itself as a leader in cell and gene therapy (CGT), with over 200 CGT technology companies and significant investments in research and development, resulting in multiple CGT products approved for market and numerous projects entering clinical stages [9]. - The city has implemented supportive policies to enhance the translation of research into clinical applications, aiming to provide innovative solutions for various diseases, including rare and autoimmune diseases [9].